Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Sep;25(9):729-32.
doi: 10.1046/j.1524-4725.1999.99035.x.

Disappointing results following resurfacing of facial skin with CO2 lasers for prophylaxis of keratoses and cancers

J E Fulton  1 , A D Rahimi, P Helton, K Dahlberg, A G Kelly
Affiliations

Disappointing results following resurfacing of facial skin with CO2 lasers for prophylaxis of keratoses and cancers

J E Fulton et al. Dermatol Surg. 1999 Sep.

Abstract

Background: With the development of the short-pulse CO2 laser it was hoped that this resurfacing would prevent recurrent actinic keratoses and basal cell cancers similar to resurfacing with dermabrasion, laser abrasion, and deep chemical peel. However, we have begun to see patients that are developing keratoses and cancers within months following laser resurfacing.

Objective: To document the problems of recurrent keratoses and basal cell cancers in patients following CO2 laser resurfacing.

Methods: Thirty-five patients with extreme sun damage were seen at 3, 6, and 12 months following CO2 laser resurfacing for repeat color and ultraviolet photography and clinical examination to look for erythematous dyskeratotic lesions or papules with pearly borders.

Results: Five of our patients (14.3%) who had undergone recent CO2 resurfacing developed actinic keratoses and basal cell cancers.

Conclusion: CO2 laser resurfacing is not as effective as dermabrasion, chemabrasion, and deep chemical peel for the prophylaxis of actinic keratoses and basal cell cancers, especially in Fitzpatrick type I and II patients.

PubMed Disclaimer

Comment in